drugset / Trial / NCT03980288
4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3
NaSingle-groupOpen-labelTreatment
Summary
A Phase I Clinical Study of 4th generation Chimeric Antigen Receptor T Cells Targeting Glypican-3 ( CAR-GPC3 T Cells) in Patients with Advanced Hepatocellular Carcinoma
Timeline
- Start
- 2019-07-23
- Primary completion
- 2020-12-30
- Completion
- 2020-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR-GPC3 T Cells | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |